遺伝子治療の世界市場レポート 2024

遺伝子治療の市場規模は、今後数年間で急激に成長すると予想されています。 2028年には21.8%の年間複合成長率（CAGR）で277億7,000万米ドルに成長すると予想されます。予測期間で予想される成長は、がん症例の増加、高齢化人口の拡大、製薬分野における研究開発支出の増加、市場内での遺伝子治療の重要性の高まりに関連している可能性があります。予測期間の主な動向には、規制当局の承認取得による事業運営の改善、戦略的提携や提携による事業活動の強化、戦略的買収による事業能力の拡大、事業拡大による事業能力の強化が含まれます。

遺伝子治療市場は、がんやその他の対象疾患の発生率の大幅な増加により成長しており、効果的な治療が必要となっています。世界のがん症例の増加は、予測期間における遺伝子治療市場の拡大に寄与すると予想されます。米国がん協会は、2022年 1月の時点で、米国で約190万人が新たにがんと診断され、609,360人ががん関連死亡すると予測しており、先進的な治療の緊急性が強調されています。肺がん、前立腺がん、腸がん、および女性の乳がんは、合わせて世界中の新規がん症例全体の43%を占めています。世界のがん発生率の増加により、細胞死を誘導したりがんの増殖を遅らせたりするための新しい遺伝子のイントロダクションを含む効果的な治療法として、遺伝子治療の需要が高まる傾向にあります。

ヘルスケア業界への投資の増加は、遺伝子治療市場の成長を促進することになるでしょう。ヘルスケア産業への投資には、医療サービス、医療機器や医薬品の製造、医療保険の提供、ヘルスケア分野への貢献に関わる企業への資金の配分が含まれます。製薬会社が特許ポートフォリオを強化し、有利なパートナーシップを確保するために戦略的に投資するため、この投資は遺伝子治療業界で極めて重要な役割を果たします。このような投資は、革新的な遺伝子治療製品の開発に役立ちます。たとえば、メディケア・メディケイド・サービスセンターによる2021年から2030年の国民医療支出（NHE）報告書に基づくと、国民医療支出は年平均5.1％増加し、2021年から2030年の間に6兆8,000億米ドル近くに達すると予測されています。 ,メディケア支出は年率7.2%で増加すると予想されているのに対し、メディケイド支出は年率5.6%増加すると予測されています。したがって、ヘルスケア業界への投資の増加は、遺伝子治療市場の成長の原動力となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界の遺伝子治療市場、遺伝子治療タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 生殖細胞系治療
• 体細胞治療
• 世界の遺伝子治療市場、ベクトル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• ウイルスベクター
• 非ウイルスベクター
• 世界の遺伝子治療市場、用途別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 腫瘍学
• 希少疾患
• 変形性膝関節症
• 神経学的障害
• 世界の遺伝子治療市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• バイオ医薬品企業
• 研究機関
• その他のエンドユーザー

第7章 地域および国の分析

• 世界の遺伝子治療市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界の遺伝子治療市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 遺伝子治療市場の競合情勢
• 遺伝子治療市場の企業プロファイル
  • UniQure NV
  • REGENXBIO Inc.
  • Bristol-Myers Squibb
  • BioMarin Pharmaceuticals Inc.
  • Jazz Pharmaceuticals Inc.

第31章 その他の大手および革新的な企業

• Biocon
• Cipla
• EdiGene Inc
• Takeda Pharmaceutical
• Daiichi Sankyo Company
• Mitsubishi Tanabe Pharma
• Merck
• GE Healthcare
• Lonza
• Pfizer
• Cellular Biomedicine Group
• GenScript
• Albumedix Ltd
• Catalent
• Freeline Therapeutics

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

Gene therapy is an approach to treating or curing diseases by modifying an individual's DNA. The mechanisms of gene treatments vary and may involve introducing a healthy copy of a gene to replace a disease-causing one or deactivating a defective gene responsible for an illness.

The primary types of gene therapy include germline therapy and somatic cell therapy. Germline therapy, also known as germline gene therapy, focuses on modifying the genes in germline cells-sperm and egg cells or their precursors. This type of genetic intervention aims to bring about changes at the hereditary level. Different vectors, such as viral vectors, non-viral vectors, and others, are utilized in gene therapy. The application of gene therapy extends to various sectors, including biopharmaceutical companies, research institutes, and other end users. It is employed in addressing conditions related to oncology, orphan diseases, knee osteoarthritis, and neurological disorders.

The gene therapy market research report is one of a series of new reports from The Business Research Company that provides gene therapy market statistics, including gene therapy industry global market size, regional shares, competitors with a gene therapy market share, detailed gene therapy market segments, market trends and opportunities, and any further data you may need to thrive in the gene therapy industry. This gene therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The gene therapy market size has grown exponentially in recent years. It will grow from $9.66 billion in 2023 to $12.64 billion in 2024 at a compound annual growth rate (CAGR) of 30.9%. The growth observed in the historical period can be ascribed to an increase in pharmaceutical research and development (R&D) spending, the escalation of public-private partnerships, government investments, and a rise in the incidence of spinal muscular atrophy.

The gene therapy market size is expected to see exponential growth in the next few years. It will grow to $27.77 billion in 2028 at a compound annual growth rate (CAGR) of 21.8%. The anticipated growth in the forecast period can be linked to a rise in cancer cases, the expanding aging population, increased research and development expenditure in the pharmaceutical sector, and a growing emphasis on gene therapy within the market. Key trends in the forecast period involve improving business operations by obtaining regulatory approvals, reinforcing business activities through strategic collaborations and partnerships, expanding business capabilities through strategic acquisitions, and enhancing operational capabilities through business expansions.

The gene therapy market is experiencing growth due to a significant increase in the incidence of cancer and other target diseases, necessitating effective treatments. The global rise in cancer cases is expected to contribute to the expansion of the gene therapy market in the forecast period. As of January 2022, the American Cancer Society predicts approximately 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the United States, highlighting the urgency for advanced treatments. Lung, prostate, bowel, and female breast cancer collectively account for 43 percent of all new cancer cases worldwide. The escalating global cancer incidence is poised to drive demand for gene therapy as an effective treatment, involving the introduction of new genes to induce cell death or slow cancer growth.

The increasing investment in the healthcare industry is set to fuel the growth of the gene therapy market. Healthcare industry investment encompasses allocating funds to companies involved in medical services, manufacturing medical equipment or drugs, offering medical insurance, and contributing to the healthcare sector. This investment plays a pivotal role in the gene therapy industry, as pharmaceutical companies strategically invest to enhance patent portfolios and secure lucrative partnerships. Such investments are instrumental in the development of innovative gene therapy products. For instance, based on the 2021-2030 National Health Expenditure (NHE) report by the Centers for Medicare & Medicaid Services, national health spending is projected to grow by an average of 5.1% annually, reaching nearly $6.8 trillion between 2021 and 2030. Moreover, Medicare spending is expected to increase at a 7.2% annual rate, while Medicaid spending is projected to rise by 5.6% annually. Hence, the increasing healthcare industry investment serves as a driving force behind the growth of the gene therapy market.

Machine learning and artificial intelligence (AI) are gradually gaining traction in the gene therapy market. AI involves simulating human intelligence in machines, Programd to exhibit natural intelligence. As a subset of AI, machine learning supports gene therapy companies in conducting comprehensive data analysis, providing insights into tumor and immune cell interactions, and delivering more accurate evaluations of tissue samples, resolving disputes among different evaluators. For example, in May 2023, Form Bio, a US-based life sciences-focused software company, introduced FORMsightAI, an innovative AI-based solution set designed to predict and optimize manufacturing outputs of cell and gene therapy constructs. This full-service solution combines adaptive AI models, Form Bio's foundational platform, and a proficient team of computational life sciences experts. FORMsightAI addresses common challenges faced by cell and gene therapy developers, including construct truncations and manufacturing contaminations, leading to improved manufacturing yields, shortened timelines to market, and enhanced therapeutic safety.

Major companies in the gene therapy market are strategically investing in the development of gene therapy facilities, such as innovation hubs, to gain a competitive advantage. Gene therapy facilities are specialized establishments for manufacturing and administering gene therapy products, aiming to correct underlying genetic issues and treat or prevent diseases. In March 2021, The Medical Research Council (MRC), LifeArc, and the Biotechnology and Biological Sciences Research Council in the UK announced substantial investments to establish a national network of cutting-edge gene therapy innovation hubs. Supported by $19 million in funding, these facilities aim to accelerate the clinical development of novel genetic therapies, potentially transforming the care of millions of patients, especially those with rare and fatal genetic disorders.

In December 2021, Novartis AG, a Swiss pharmaceutical company, acquired Gyroscope Therapeutics Holdings plc for $800 million. Through this acquisition, Novartis expands its gene therapy research capabilities by adding GT005, an experimental one-time gene therapy in Phase 2 for treating geographic atrophy (GA). This move enhances Novartis's commitment to ophthalmic innovation, contributing to the global effort to treat and prevent blindness related to eye diseases. Gyroscope Therapeutics Holdings PLC, based in the UK, is a clinical-stage biopharmaceutical company specializing in the research and development of gene therapies for eye-related diseases.

Major companies operating in the gene therapy market report are UniQure NV, REGENXBIO Inc., Bristol-Myers Squibb, BioMarin Pharmaceuticals Inc., Jazz Pharmaceuticals Inc., Biocon, Cipla, EdiGene Inc., Takeda Pharmaceutical, Daiichi Sankyo Company, Mitsubishi Tanabe Pharma, Merck, GE Healthcare, Lonza, Pfizer, Cellular Biomedicine Group, GenScript, Albumedix Ltd., Catalent, Freeline Therapeutics, DiNAQOR AG, Vivet Therapeutics, Allergan, Amgen, Biocad, Celgene Corporation, Johnson & Johnson, Eli Lilly and Company, AstraZeneca, Bayer AG, Juno Therapeutics, Allogene Therapeutics, Bluebird Bio, Regen BioPharma, Bellicum, Biotchpharma, BrainStorm Cell Therapeutics, Pluristem, Sanofi

North America was the largest region in the gene therapy market in 2023. The regions covered in the gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the gene therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The gene therapy market includes revenues earned by entities by replacing a disease-causing gene with a healthy copy of the gene and inactivating a disease-causing gene that is not functioning properly. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gene Therapy Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gene therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gene therapy? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gene therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Gene Therapy Type: Germline Therapy; Somatic Cell Therapy
• 2) By Vector: Viral Vector; Non-Viral Vector
• 3) By Application: Oncology; Orphan Disease; Knee Osteoarthritis; Neurological Disorders
• 4) By End Users: Biopharmaceutical Companies; Research Institutes; Other End Users
• Companies Mentioned: UniQure NV; REGENXBIO Inc.; Bristol-Myers Squibb; BioMarin Pharmaceuticals Inc.; Jazz Pharmaceuticals Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Gene Therapy Market Characteristics

3. Gene Therapy Market Trends And Strategies

4. Gene Therapy Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Gene Therapy Market Size and Growth

• 5.1. Global Gene Therapy Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Gene Therapy Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Gene Therapy Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Gene Therapy Market Segmentation

• 6.1. Global Gene Therapy Market, Segmentation By Gene Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Germline Therapy
• Somatic Cell Therapy
• 6.2. Global Gene Therapy Market, Segmentation By Vector, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Viral Vector
• Non-Viral Vector
• 6.3. Global Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Oncology
• Orphan Disease
• Knee Osteoarthritis
• Neurological Disorders
• 6.4. Global Gene Therapy Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Biopharmaceutical Companies
• Research Institutes
• Other End Users

7. Gene Therapy Market Regional And Country Analysis

• 7.1. Global Gene Therapy Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Gene Therapy Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Gene Therapy Market

• 8.1. Asia-Pacific Gene Therapy Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Gene Therapy Market, Segmentation By Gene Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Gene Therapy Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Gene Therapy Market

• 9.1. China Gene Therapy Market Overview
• 9.2. China Gene Therapy Market, Segmentation By Gene Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Gene Therapy Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Gene Therapy Market

• 10.1. India Gene Therapy Market, Segmentation By Gene Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Gene Therapy Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Gene Therapy Market

• 11.1. Japan Gene Therapy Market Overview
• 11.2. Japan Gene Therapy Market, Segmentation By Gene Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Gene Therapy Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Gene Therapy Market

• 12.1. Australia Gene Therapy Market, Segmentation By Gene Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Gene Therapy Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Gene Therapy Market

• 13.1. Indonesia Gene Therapy Market, Segmentation By Gene Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Gene Therapy Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Gene Therapy Market

• 14.1. South Korea Gene Therapy Market Overview
• 14.2. South Korea Gene Therapy Market, Segmentation By Gene Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Gene Therapy Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Gene Therapy Market

• 15.1. Western Europe Gene Therapy Market Overview
• 15.2. Western Europe Gene Therapy Market, Segmentation By Gene Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Gene Therapy Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Gene Therapy Market

• 16.1. UK Gene Therapy Market, Segmentation By Gene Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Gene Therapy Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Gene Therapy Market

• 17.1. Germany Gene Therapy Market, Segmentation By Gene Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Gene Therapy Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Gene Therapy Market

• 18.1. France Gene Therapy Market, Segmentation By Gene Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Gene Therapy Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Gene Therapy Market

• 19.1. Italy Gene Therapy Market, Segmentation By Gene Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Gene Therapy Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Gene Therapy Market

• 20.1. Spain Gene Therapy Market, Segmentation By Gene Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Gene Therapy Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Gene Therapy Market

• 21.1. Eastern Europe Gene Therapy Market Overview
• 21.2. Eastern Europe Gene Therapy Market, Segmentation By Gene Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Gene Therapy Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Gene Therapy Market

• 22.1. Russia Gene Therapy Market, Segmentation By Gene Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Gene Therapy Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Gene Therapy Market

• 23.1. North America Gene Therapy Market Overview
• 23.2. North America Gene Therapy Market, Segmentation By Gene Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Gene Therapy Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Gene Therapy Market

• 24.1. USA Gene Therapy Market Overview
• 24.2. USA Gene Therapy Market, Segmentation By Gene Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Gene Therapy Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Gene Therapy Market

• 25.1. Canada Gene Therapy Market Overview
• 25.2. Canada Gene Therapy Market, Segmentation By Gene Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Gene Therapy Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Gene Therapy Market

• 26.1. South America Gene Therapy Market Overview
• 26.2. South America Gene Therapy Market, Segmentation By Gene Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Gene Therapy Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Gene Therapy Market

• 27.1. Brazil Gene Therapy Market, Segmentation By Gene Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Gene Therapy Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Gene Therapy Market

• 28.1. Middle East Gene Therapy Market Overview
• 28.2. Middle East Gene Therapy Market, Segmentation By Gene Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Gene Therapy Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Gene Therapy Market

• 29.1. Africa Gene Therapy Market Overview
• 29.2. Africa Gene Therapy Market, Segmentation By Gene Therapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Gene Therapy Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Gene Therapy Market, Segmentation By End Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Gene Therapy Market Competitive Landscape And Company Profiles

• 30.1. Gene Therapy Market Competitive Landscape
• 30.2. Gene Therapy Market Company Profiles
  • 30.2.1. UniQure NV
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. REGENXBIO Inc.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Bristol-Myers Squibb
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. BioMarin Pharmaceuticals Inc.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Jazz Pharmaceuticals Inc.
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Gene Therapy Market Other Major And Innovative Companies

• 31.1. Biocon
• 31.2. Cipla
• 31.3. EdiGene Inc
• 31.4. Takeda Pharmaceutical
• 31.5. Daiichi Sankyo Company
• 31.6. Mitsubishi Tanabe Pharma
• 31.7. Merck
• 31.8. GE Healthcare
• 31.9. Lonza
• 31.10. Pfizer
• 31.11. Cellular Biomedicine Group
• 31.12. GenScript
• 31.13. Albumedix Ltd
• 31.14. Catalent
• 31.15. Freeline Therapeutics

32. Global Gene Therapy Market Competitive Benchmarking

33. Global Gene Therapy Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Gene Therapy Market

35. Gene Therapy Market Future Outlook and Potential Analysis

• 35.1 Gene Therapy Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Gene Therapy Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Gene Therapy Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer